Endothelial Progenitor Cells with Stem Cells Enhance Osteogenic Efficacy.

Qiong Li,Tao Yu,Fang Wang,Xin Liu,Zuolin Wang
2020-01-01
Abstract:BACKGROUND:Mesenchymal stem cell (MSC)-based bone tissue engineering is a promising treatment option for maxillary sinus augmentation. Rapid vascularization is necessary to enhance the osteoinductive efficacy and prevent necrosis of the tissue-engineered bone. This study investigated whether the co-autotransplantation of endothelial progenitor cells (EPCs) could significantly enhance the in vivo osteogenic efficacy of MSCs and prevent necrosis of the tissue-engineered bone in a maxillary sinus augmentation model in dogs.METHODS:We evaluated the in vitro osteogenic activities of a clinically-used scaffold-deproteinized bovine bone (Bio-Oss) by examining cell adhesion and alkaline phosphatase (ALP) activity. In vivo, sinus augmentations were performed identically on both sides of dogs (n = 3 per group) using three treatment groups: (A) Bio-Oss with MSCs and EPCs; (B) Bio-Oss with MSCs; and (C) Bio-Oss with EPCs. The tissue implants were evaluated 24 weeks post-implantation.RESULTS:In vitro, co-application of EPCs and MSCs on Bio-Oss significantly enhanced adhesion and ALP activity. In vivo, co-autotransplantation of MSCs and EPCs resulted in a significantly higher height, compressive strength, bone volume density, trabecular thickness, and trabecular number and a significantly lower trabecular separation compared with the other groups. The fluorescent test showed co-autotransplantation caused a significantly higher mineral apposition rate than the other groups. Histomorphometric analysis showed co-application resulted in the highest rate of new bone formation. Newly formed bone was frequently in the center of the implants with EPCs and MSCs, but not the other implants.CONCLUSIONS:Co-autotransplantation of EPCs and MSCs significantly enhanced the in vivo osteogenic efficacy, suggesting promising potential for sinus augmentation.
What problem does this paper attempt to address?